Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies

Bone Marrow Transplantation volume 53, pages 129–137 (2018)Cite this article

Subjects

Abstract

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Loberiza FR, Zhang M-J, Lee SJ, Klein JP, LeMaistre CF, Serna DS et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979–2987.

    CAS  PubMed  Google Scholar 

  2. Changsirikulchai S, Myerson D, Guthrie Kal, McDonald GB, Alpers CE, Hingorani SR . Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009; 4: 345–353.

    PubMed  PubMed Central  Google Scholar 

  3. Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK . Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22: 12–20.

    CAS  PubMed  Google Scholar 

  4. Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.

    CAS  PubMed  Google Scholar 

  5. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191–204.

    PubMed  Google Scholar 

  6. George JN, Selby GB . Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 2004; 33: 1073–1074.

    CAS  PubMed  Google Scholar 

  7. Cho B-S, Yahng S-A, Lee S-E, Eom K-S, Kim Y-J, Kim H-J et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 918–926.

    CAS  PubMed  Google Scholar 

  8. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.

    PubMed  Google Scholar 

  9. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.

    PubMed  Google Scholar 

  10. Thachil J . Nitric oxide in transplantation-related thrombotic microangiopathy. Bone Marrow Transplant 2009; 43: 513–514.

    CAS  PubMed  Google Scholar 

  11. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM . The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010; 56: 1168–1174.

    PubMed  PubMed Central  Google Scholar 

  12. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013; 96: 217–223.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ricklin D, Cines DB . TMA: beware of complements. Blood 2013; 122: 1997–1999.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Dhakal P, Bhatt VR . Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017; 52: 352–356.

    CAS  PubMed  Google Scholar 

  15. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013; 161: 279–280.

    PubMed  Google Scholar 

  16. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20: 518–525.

    CAS  PubMed  Google Scholar 

  17. Jodele S, Laskin B, Fukuda T, Vinks A, Mizuno K, Goebel J et al. Eculizumab treatment improves survival in patients with high-risk hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TMA). Biol Blood Marrow Transplant 2015; 21: S225–S226.

    Google Scholar 

  18. Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM . Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292–299.

    CAS  PubMed  Google Scholar 

  19. Cohen H, Bull HA, Seddon A, Enayat MS, Hill FG, Woolf N et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989; 43: 207–214.

    CAS  PubMed  Google Scholar 

  20. Nürnberger W, Michelmann I, Burdach S, Göbel U . Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61–65.

    PubMed  Google Scholar 

  21. Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010; 16: 985–993.

    CAS  PubMed  Google Scholar 

  22. Graf L, Stern M . Acute phase after haematopoietic stem cell transplantation: bleeding and thrombotic complications. Hamostaseologie 2012; 32: 56–62.

    CAS  PubMed  Google Scholar 

  23. Tsakiris DA, Tichelli A . Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Best Pract Res Clin Haematol 2009; 22: 137–145.

    PubMed  Google Scholar 

  24. Nadir Y, Brenner B . Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res 2007; 120 (Suppl): S92–S98.

    PubMed  Google Scholar 

  25. Tichelli A, Gratwohl A . Vascular endothelium as “novel” target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139–148.

    CAS  PubMed  Google Scholar 

  26. Nadir Y, Hoffman R, Brenner B . Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004; 8: E4.

    PubMed  Google Scholar 

  27. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638–644.

    PubMed  Google Scholar 

  28. Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A . Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484–493.

    PubMed  Google Scholar 

  29. Roy V, Rizvi MA, Vesely SK, George JN . Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641–646.

    CAS  PubMed  Google Scholar 

  30. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327–329.

    CAS  PubMed  Google Scholar 

  31. Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525–531.

    PubMed  Google Scholar 

  32. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551–557.

    CAS  PubMed  Google Scholar 

  33. Rosenthal RA, Chukwuogo NA, Ocasio VH, Kahng KU . Cyclosporine inhibits endothelial cell prostacyclin production. J Surg Res 1989; 46: 593–596.

    CAS  PubMed  Google Scholar 

  34. Burke GW, Ciancio G, Cirocco R, Markou M, Olson L, Contreras N et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999; 68: 1336–1342.

    CAS  PubMed  Google Scholar 

  35. Robson M, Côte I, Abbs I, Koffman G, Goldsmith D . Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324–327.

    PubMed  Google Scholar 

  36. Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y . Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant 2010; 45: 689–693.

    CAS  PubMed  Google Scholar 

  37. Takatsuka H, Wakae T, Mori A, Okada M, Fujimori Y, Takemoto Y et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31: 475–479.

    CAS  PubMed  Google Scholar 

  38. Goon PKY, Lip GYH, Boos CJ, Stonelake PS, Blann AD . Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005; 3: 1301–1308.

    CAS  PubMed  Google Scholar 

  40. Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006; 81: 1405–1409.

    PubMed  Google Scholar 

  41. Erdbruegger U, Woywodt A, Kirsch T, Haller H, Haubitz M . Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy. Am J Kidney Dis 2006; 48: 564–570.

    PubMed  Google Scholar 

  42. Nochy D, Lefaucheur C, Hill G . VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 359: 206 author reply 206–207.

    CAS  PubMed  Google Scholar 

  43. Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B . Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 942–947.

    CAS  PubMed  Google Scholar 

  44. Meri S . Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013; 24: 496–502.

    CAS  PubMed  Google Scholar 

  45. Noris M, Mescia F, Remuzzi G . STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622–633.

    CAS  PubMed  Google Scholar 

  46. Noris M, Remuzzi G . Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–1687.

    CAS  PubMed  Google Scholar 

  47. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003–2007.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG . Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008; 85: 22–28.

    PubMed  Google Scholar 

  49. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Refined diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood 2014; 124: 645–654.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Kanamori H, Maruta A, Sasaki S, Yamazaki E, Ueda S, Katoh K et al. Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 1998; 21: 705–709.

    CAS  PubMed  Google Scholar 

  51. Zeigler Z, Kelton J, Moore J, Shadduck R, Andrews DF, Nath R et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999; 24: 641–645.

    CAS  PubMed  Google Scholar 

  52. Muto H, Ohashi K, Ando M, Akiyama H, Sakamaki H . Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2010; 91: 471–477.

    PubMed  Google Scholar 

  53. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris Da et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 36: 993–1000.

    CAS  PubMed  Google Scholar 

  55. Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112–1119.

    PubMed  Google Scholar 

  56. Laskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.

    CAS  PubMed  Google Scholar 

  57. Cho B-S, Min C-K, Eom K-S, Kim Y-J, Kim H-J, Lee S et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 813–820.

    PubMed  Google Scholar 

  58. Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S . Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 2010; 45: 699–704.

    CAS  PubMed  Google Scholar 

  59. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN . Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009; 49: 392–394.

    PubMed  Google Scholar 

  60. Thachil J . The role for adjunctive treatment to plasma exchange in thrombotic thrombocytopenic purpura. Nephrol Dial Transplant 2008; 23: 2701–22.

    PubMed  Google Scholar 

  61. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion 2013; 53: 661–667.

    CAS  PubMed  Google Scholar 

  62. Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985–991.

    CAS  PubMed  Google Scholar 

  63. Choi CM, Schmaier AH, Snell MR, Lazarus HM . Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009; 69: 183–198.

    CAS  PubMed  Google Scholar 

  64. Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006; 38: 445–451.

    CAS  PubMed  Google Scholar 

  65. Mandelbrot D . Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation. J Am Soc Nephrol 2009; 20: 1170–1171.

    CAS  PubMed  Google Scholar 

  66. Dhakal P, Giri S, Pathak R, Bhatt VR . Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2017; 23: 175–180.

    CAS  PubMed  Google Scholar 

  67. Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 307–315.

    CAS  PubMed  Google Scholar 

  68. Schröder H . Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol 1995; 47: 250–252.

    PubMed  Google Scholar 

  69. Au W-Y, Ma ES, Lee T-L, Ha S-Y, Fung AT, Lie AKW et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475–478.

    CAS  PubMed  Google Scholar 

  70. Marr H, McDonald E-J, Merriman E, Smith M, Mangos H, Stoddart C et al. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J 2009 3 122: 72–74.

    PubMed  Google Scholar 

  71. Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J et al. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant 2012; 16: E39–E42.

    PubMed  Google Scholar 

  72. Masini E, Lupini M, Mugnai L, Raspanti S, Mannaioni PF . Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br J Pharmacol 1995; 115: 629–635.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Nishimura M, Nanbu A, Komori T, Ohtsuka K, Takahashi H, Yoshimura M . Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats. Clin Exp Pharmacol Physiol 2000; 27: 618–624.

    CAS  PubMed  Google Scholar 

  74. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101: 8497–8502.

    CAS  PubMed  Google Scholar 

  75. Kajiume T, Nagita A, Yoshimi S, Kobayashi K, Kataoka N . A case of hemolytic uremic syndrome improved with nitric oxide. Bone Marrow Transplant 2000; 25: 109–110.

    CAS  PubMed  Google Scholar 

  76. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC . Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007; 293: H1115–H1121.

    CAS  PubMed  Google Scholar 

  77. Inoue Y, Kosugi S, Miura I, Hatta Y, Takeuchi J . Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res 2011; 127: 603–604.

    CAS  PubMed  Google Scholar 

  78. Okada K, Horino A, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y et al. [Successful treatment for thrombotic microangiopathy with recombinant human soluble thrombomodulin after umbilical cord blood transplantation]. Rinsho Ketsueki 2012; 53: 235–239.

    PubMed  Google Scholar 

  79. Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015–4022.

    CAS  PubMed  Google Scholar 

  80. Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 2017; 102: 466–475.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094–2101.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura J-i, Nunn MA et al. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv 2017; 1: 1254–1258.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westchester Medical Center, Valhalla, NY, USA

    J Khosla

  2. Hematology/Oncology Infusion Unit, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    A C Yeh, T R Spitzer & B R Dey

Authors
  1. J Khosla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A C Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T R Spitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B R Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B R Dey.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khosla, J., Yeh, A., Spitzer, T. et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 53, 129–137 (2018). https://doi.org/10.1038/bmt.2017.207

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.207

This article is cited by

Search

Advanced search

Quick links